Miura Partners Invests in Farmadosis for Global Growth

Miura Partners, a prominent private equity firm based in Barcelona, has secured a significant stake in Farmadosis, a Mallorcan innovator in automated medication dispensing. This strategic investment is designed to fuel Farmadosis's ambitious global expansion plans and solidify its leadership in the rapidly evolving pharmacy automation sector.

Founded in 2012, Farmadosis has carved out a niche by developing sophisticated robotics and systems for the precise preparation and management of pharmaceuticals. Serving a diverse clientele that includes pharmacies, hospitals, and elder care facilities, the company's technology is crucial for enhancing patient safety and operational efficiency within healthcare settings. With a presence already established in over 25 countries across Europe, Latin America, and the Middle East, Farmadosis is well-positioned for accelerated international growth.

The financial backing from Miura Partners, specifically through its Miura Impact Fund, will be instrumental in scaling Farmadosis's operations. While the exact investment sum and equity percentage remain undisclosed, the partnership signals a strong confidence in the company's trajectory. Farmadosis, which currently employs around 50 individuals and generates approximately €15 million in annual revenue with consistent double-digit growth, aims to leverage this capital for both organic expansion and potential strategic acquisitions.

This move aligns perfectly with key healthcare industry trends. The increasing burden on healthcare systems, driven by an aging global population, a rise in chronic diseases, and persistent shortages of pharmacy and nursing staff, creates a compelling demand for automation solutions. Farmadosis's automated dose preparation systems directly address these challenges by minimizing medication errors and improving the traceability of pharmaceuticals, thereby enhancing overall patient care and reducing systemic inefficiencies.

The leadership team at Farmadosis will remain intact to guide this new chapter. Founder Asier Zubillaga will continue to focus on business and product development, while CEO Joaquín González will oversee the company's strategic direction. This continuity ensures that the company's innovative spirit and operational expertise remain central to its growth strategy.

Farmadosis's commitment to innovation was recently underscored by a distribution agreement with Korean automation specialist Cretem, aimed at broadening its service portfolio across the European market. The company's regional success was also recognized with the "Small Business of the Year" award in the Balearic Islands, highlighting its significant impact within its home territory.

The investment by Miura Partners is a clear indicator of the growing investor appetite for healthtech solutions that offer tangible improvements in healthcare delivery. As the global pharmacy automation market continues its upward trajectory, driven by the need for greater precision and efficiency, Farmadosis, with the support of Miura Partners, is set to become a major player on the international stage.